V3V Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Biobanking RevenueThe combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.
Improving Revenue And MarginsStrong TTM revenue growth alongside a gross-margin recovery and positive EBITDA indicates meaningful operating improvement. If maintained, this combination can increase contribution from the existing business, support reinvestment, and improve the path toward sustainable profitability.
Positive Recent Cash GenerationPositive operating and free cash flow provide internally generated funding for ongoing operations and reduce immediate reliance on external capital. This is an important fundamental strength because cash generation has improved even while reported net income remains negative.
Bears Say
Ongoing Net LossesPersistent operating and net losses weaken earnings quality and limit the company’s ability to build equity through retained profits. Until profitability improves, cash generation may not translate into durable earnings strength, leaving the business more exposed to execution setbacks.
High Leverage And Thin EquityA sharply higher debt-to-equity ratio and small equity cushion reduce financial flexibility relative to the asset base. This structure can constrain investment choices, increase sensitivity to operating weakness, and make balance-sheet repair dependent on improved results or additional capital.
Volatile Cash-flow ConsistencyRecent positive cash flow is encouraging, but the history of negative operating cash flow and sharply negative latest free-cash-flow growth indicates an unstable run-rate. Inconsistent conversion can complicate funding decisions and reduce confidence that current cash generation will persist.
V3V FAQ
What was VITA 34 AG’s price range in the past 12 months?
Currently, no data Available
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is CHF47.98M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is Nov 30, 2026 which is in 84 days.
How were VITA 34 AG’s earnings last quarter?
VITA 34 AG released its earnings results on Aug 28, 2026. The company reported -CHF0.06 earnings per share for the quarter.
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Undervalued.
Does VITA 34 AG pay dividends?
VITA 34 AG does not currently pay dividends.
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
VITA 34 AG has 17,640,104 shares outstanding.
What happened to VITA 34 AG’s price movement after its last earnings report?
VITA 34 AG reported an EPS of -CHF0.06 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in CH:V3V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
VITA 34 AG
VITA 34 AG is dedicated to the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. Its operations span Germany, Spain, and global markets. The company actively develops a range of advanced therapeutic solutions, including cell and gene therapies, specialized cell therapeutic procedures, cryopreservation of a patient's own immune cells, and CAR-T cell technology. Furthermore, VITA 34 manufactures advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells for experimental applications by specialized medical institutions. It also preserves stem cells from perinatal tissues and adult body fat, and provides contract manufacturing for pharmaceutical intermediates. Founded in 1997, VITA 34 AG is headquartered in Leipzig, Germany.